SAN DIEGO, Feb. 10, 2016 -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that the Company’s Chief Executive Officer, Dr. Stuart W. Titus, will deliver a historic keynote address on cannabidiol (CBD) at the VII Mexico City World Anti-Aging Congress on February 13th.
The global healthcare conference takes place February 12th – 14th at the Hotel Fiesta Americana Reforma, Mexico City. Last week, Mexico’s government (COFEPRIS) issued the first permits for individuals to begin importation of CBD hemp oil (RSHO-X™) with a doctor’s recommendation. This global healthcare education event represents the first opportunity for the medical community to receive hands-on education about CBD directly from the Chief Executive Officer of Medical Marijuana, Inc.
“We are extremely honored to participate in the VII Mexico City World Anti-Aging Congress to educate the healthcare community in Mexico about CBD,” says Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “Our presentation will address the unique anti-aging properties of the hemp cannabis, research that supports cannabinoids as anti-oxidants and neuroprotectants, and why hemp is widely regarded as a ‘whole food’ and ‘superfood’ throughout the world.”
The VII Mexico City World Anti-aging Congress (Congreso Mundial en Medicina Antienvejecimiento AMA Mexico) event details are:
Congreso Mundial en Medicina Antienvejecimiento AMA Mexico
7th A4M Anti-Aging and Regenerative Medicine
Exhibit Space #19 – HempMeds® Mexico
12-14/02/2016
Puebla Privada Jalisco 8
Colonia El Carmen 7200
Tel: +56 80 65 68 or E-mail
www.medicina-antienvejecimiento.net
Venue: Hotel Fiesta Americana Reforma, Mexico City
For instructions on how to begin the RSHO-XTM import process, contact COFEPRIS for details. For information on RSHO-X™ product availability in Mexico, click here to register with HempMeds® Mexico website at http://www.hempmeds.mx. To speak with a HempMeds® Mexico representative, contact the customer service department at:
US: 1-866-786-2440
MX: 001-883-786-2440
Attention Members of the News Media:
Contact Andrew Hard to pre-register for a media pass to cover the historic keynote address and conduct interviews at the HempMeds® Mexico exhibit #19. Phone: 917.660.5418 or email to: [email protected]
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company, created to provide access to cannabinoid-based products including cannabidiol (CBD) hemp oil products as they become legal in the country of Mexico for the first time. Our Company is a sales, marketing and distribution company. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to our CBD hemp oil products. HempMeds® Mexico is the first company to legally ship RSHO-XTM CBD hemp oil into Mexico. For more information, please review the company’s website at: http://hempmeds.mx/.
About HempMeds®
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: Public Relations contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 [email protected] www.cmwmedia.com Corporate contact: Medical Marijuana, Inc. Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc


Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
9 Tips for Avoiding Tax Season Cyber Scams
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



